title: Nonalcoholic fatty liver disease: current and potential therapies.
abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury worldwide. It covers a wide spectrum of hepatic disorders ranging from simple steatosis, through steatohepatitis (steatosis with inflammation), to cirrhosis. The molecular and cellular mechanisms underlying hepatic injury in NAFLD are not clear. Several evidences suggest that multiple mechanisms including insulin resistance, oxidative stress, inflammation, and genetic factors interact to initiate the development of NAFLD. Despite that there is currently no approved drug therapy for NAFLD, many approaches appear to be beneficial. Insulin sensitizers, antioxidants and antiinflammatory agents showed promising effects. This review highlights the current as well as the potential therapies of NAFLD.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Minia University, Egypt. maim69@yahoo.com
authors.forename: Mohamed Abdellah
authors.initials: MA
authors.lastname: Ibrahim
authors.forename: Mina
authors.initials: M
authors.lastname: Kelleni
authors.forename: Ayman
authors.initials: A
authors.lastname: Geddawy
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use; D005234:Fatty Liver / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology; D008930:Mitochondria, Liver / Q000502:physiology; D018384:Oxidative Stress / Q000502:physiology
chemical_list: D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents